公开(公告)号：HU0200355A2

公开(公告)日：2002-06-29

申请号：HU0200355

申请日：1999-09-17

Applicant: BASF AG

Inventor： ARNOLD LEE D ,  CALDERWOOD DAVID ,  DENG BOJUAN B ,  HIRST GAVIN ,  MAZDIYASNI HORMOZ

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：NO20011357L

公开(公告)日：2001-05-14

申请号：NO20011357

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE DANIEL ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN C ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：AU752474B2

公开(公告)日：2002-09-19

申请号：AU6047599

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  JOHNSTON DAVID N ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：BR9913888A

公开(公告)日：2002-01-08

申请号：BR9913888

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B ,  JOHNSTON DAVID N ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：ID28362A

公开(公告)日：2001-05-17

申请号：ID20010653

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：PL347138A1

公开(公告)日：2002-03-25

申请号：PL34713899

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B ,  JOHNSTON DAVID N ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：CZ2001959A3

公开(公告)日：2001-12-12

申请号：CZ2001959

申请日：1999-09-17

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE D ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505 ,  A61P35/04

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：NO20011357A

公开(公告)日：2001-05-14

申请号：NO20011357

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE DANIEL ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN C ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

CPC classification number: C07D487/04

公开(公告)号：NO20011357D0

公开(公告)日：2001-03-16

申请号：NO20011357

申请日：2001-03-16

Applicant: BASF AG

Inventor： CALDERWOOD DAVID ,  ARNOLD LEE DANIEL ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN C ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  C07D

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

公开(公告)号：SK3852001A3

公开(公告)日：2003-03-04

申请号：SK3852001

申请日：1999-09-17

Applicant: BASF AG

Inventor： JOHNSTON DAVID N ,  RAFFERTY PAUL ,  TOMETZKI GERALD B ,  TWIGGER HELEN L ,  MUNSCHAUER RAINER ,  CALDERWOOD DAVID ,  ARNOLD LEE ,  MAZDIYASNI HORMOZ ,  HIRST GAVIN ,  DENG BOJUAN B

IPC: A61K31/519 ,  A61P1/04 ,  A61P3/10 ,  A61P9/00 ,  A61P11/00 ,  A61P15/00 ,  A61P17/02 ,  A61P19/02 ,  A61P27/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07D487/04 ,  A61K31/505

Abstract: Chemical compounds having structural formula (I) and physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disease states where angiogenesis or endothelial cell hyperproliferative is a factor. These compounds can be used to treat cancer, hyperproliferation disorders, rheumatoid arthritis, disorders of the immune system, transplant rejection, and inflammatory disorders.